Literature DB >> 15135317

Increased levels of cyclic adenosine monophosphate contribute to the hyporesponsiveness of mast cells in alloxan diabetes.

Emiliano O Barreto1, Vinicius F Carvalho, Vincent Lagente, Claire Lugnier, Renato S B Cordeiro, Marco A Martins, Patrícia M R E Silva.   

Abstract

In this study, we investigated the influence of intracellular cyclic adenosine monophosphate (cAMP) changes on the rat mast cell hyporesponsiveness following immunological and non-immunological stimuli. Compared with mast cells from normal rats, those recovered from 21-day diabetic animals showed a significant augmentation in the intracellular levels of cAMP, in directly correlated with secretion of lower amounts of histamine after stimulation with antigen, bradykinin and compound 48/80 in vitro. Incubation of normal mast cells with selective inhibitors of phosphodiesterase type 4 (PDE 4) rolipram, NCS 613 and RP 73401, or the cell permeable analogue N6-2'-O-dibutyryladenosine 3':5'-cyclic monophosphate (db cAMP), led to a decrease of histamine secretion in vitro. However, the effectiveness of either NCS 613 or db cAMP in inhibiting antigen-induced degranulation is comparable in both normal and diabetic mast cells. We suggest that (a) there is a close correlation between higher levels of intracellular cAMP and hyporesponsiveness of diabetic mast cells, phenomena probably associated with a reduction in the expression and/or activity of PDE 4 and that (b) the mechanism of cAMP-mediated down-regulation of mast cell function is saturated in diabetic rats. Copyright 2004 Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15135317     DOI: 10.1016/j.intimp.2004.03.001

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  2 in total

1.  Mast cell function and death in Trypanosoma cruzi infection.

Authors:  Marcelo Meuser-Batista; José Raimundo Corrêa; Vinícius Frias Carvalho; Constança Felícia De Paoli de Carvalho Britto; Otacilio da Cruz Moreira; Marcos Meuser Batista; Maurílio José Soares; Francisco Alves Farias Filho; Patrícia Machado R E Silva; Joseli Lannes-Vieira; Robson Coutinho Silva; Andrea Henriques-Pons
Journal:  Am J Pathol       Date:  2011-08-03       Impact factor: 4.307

2.  Disease progression in MRL/lpr lupus-prone mice is reduced by NCS 613, a specific cyclic nucleotide phosphodiesterase type 4 (PDE4) inhibitor.

Authors:  Thérèse Keravis; Fanny Monneaux; Issaka Yougbaré; Lucien Gazi; Jean-Jacques Bourguignon; Sylviane Muller; Claire Lugnier
Journal:  PLoS One       Date:  2012-01-11       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.